Cardiovascular

Latest News

Hurricane damage to boats and shoreline | Macbeth GP - stock.adobe.com
How Climate Change Leads to Worse Cardiovascular Health

June 12th 2024

Extreme temperatures and hurricanes are strongly associated with worsening cardiovascular health, a study as foundfinds.

Xylitol sweetener | womue - stock.adobe.com
Sugar Substitute Xylitol Linked to Cardiovascular Risk

June 11th 2024

AJMC
Limited English Proficiency, Cardiovascular Risk Factors, Cardiovascular Disease, and In-Hospital COVID-19 Outcomes

June 10th 2024

Magnesium pills | Image Credit: Dmitriy - stock.adobe.com
High Magnesium Depletion Scores Linked to Increased Mortality in US Patients With Hypertension

June 7th 2024

Center on Health Equity and Access
Health Equity and Access Weekly Roundup: June 1, 2024

June 1st 2024

Continuing Medical Education
June 15th 2024

Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejection Fraction

1.0 Credits / Cardiology
June 15th 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
June 15th 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

Early Look at ACC Navigator Program Shows Inpatient Mortality Drops as Hospitals Take Positive Steps
February 26th 2018

Early Look at ACC Navigator Program Shows Inpatient Mortality Drops as Hospitals Take Positive Steps

Mary Caffrey
In the next phase of the program, researchers will dig into the data they have gathered so far to identify the best practices for reducing 30- and 90-day readmission rates.
MedPAC Reports Lower Readmission Rates and Reduced Medicare Spending With HRRP
February 9th 2018

MedPAC Reports Lower Readmission Rates and Reduced Medicare Spending With HRRP

Surabhi Dangi-Garimella, PhD
According to the Medicare Payment Advisory Commission (MedPAC), hospital readmission rates have fallen following implementation of the Hospital Readmissions Reduction Program (HRRP), and HRRP did not have a negative impact on mortality rates.
Genetic Testing a Must for Relatives of Cardiomyopathy Patients
February 5th 2018

Genetic Testing a Must for Relatives of Cardiomyopathy Patients

Kaitlynn Ely
With 4 in 10 cardiomyopathies having genetic links, there is a need for relatives of patients with cardiomyopathy to be screened in order to prevent early death, according to a recent study published in European Heart Journal.
Catheter Ablation More Effective Than Traditional Therapy in Atrial Fibrillation
February 3rd 2018

Catheter Ablation More Effective Than Traditional Therapy in Atrial Fibrillation

Samantha DiGrande
A new study published in the February issue of the New England Journal of Medicine found that patients that received radiofrequency catheter ablation compared with traditional drug therapies for atrial fibrillation (AF) had significantly lower hospitalization and mortality rates.
Higher Resting Heart Rate Associated With Adverse CV, Non-CV Events
February 1st 2018

Higher Resting Heart Rate Associated With Adverse CV, Non-CV Events

Jaime Rosenberg
Higher resting heart rate (HR) and increases in HR over time are associated with increased risk of adverse cardiovascular (CV) and non-CV events, such as incident heart failure and all-cause mortality, according to a study published in JAMA Cardiology.
Site Logo
February 1st 2018

Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Prime Therapeutics, Boehringer-Ingelheim Reach Outcomes-Based Contract for Jardiance
January 30th 2018

Prime Therapeutics, Boehringer-Ingelheim Reach Outcomes-Based Contract for Jardiance

Mary Caffrey
Empagliflozin (Jardiance) and another SGLT2 inhibitor, canagliflozin (Invokana) have been competing aggressively; both have clinical trial results showing cardiovascular benefits.
Site Logo
January 25th 2018

ODYSSEY Outcomes Results for Sanofi's Praluent to Lead Off ACC Meeting

Mary Caffrey
The annual meeting of the American College of Cardiology (ACC), which runs March 10-12, 2018, in Orlando, Florida, will open with cardiovascular outcomes results for the PCSK9 inhibitor alirocumab (Praluent). The meeting also features updates on anti-inflammatory drugs, the use of SGLT2 inhibitors in heart failure, and how cardiology is shifting to new healthcare delivery models.
Study Finds Prior Authorization Mandates for PCSK9 Drugs Raise Questions of Access
January 20th 2018

Study Finds Prior Authorization Mandates for PCSK9 Drugs Raise Questions of Access

Mary Caffrey
Researchers were especially concerned about barriers for patients with familial hypercholesterolemia, whose needs would seem clear cut but who nonetheless faced costly hurdles, such as genetic testing.
Site Logo
January 17th 2018

A Cost-Effectiveness Analysis of Cardiology eConsults for Medicaid Patients

Daren Anderson, MD Victor Villagra, MD Emil N. Coman, PhD Ianita Zlateva, MPH Alex Hutchinson, MBA Jose Villagra, BS J. Nwando Olayiwola, MD, MPH
A randomized trial of eConsults for cardiology referrals from primary care resulted in significant reductions in total cost of care compared with traditional face-to-face consultations.
Dr Amar Bhakta on Changing the Approach to Treating Heart Failure
January 13th 2018

Dr Amar Bhakta on Changing the Approach to Treating Heart Failure

Reimbursement structures and population demographics change the way hospitals approach heart failure, explained Amar Bhakta, MD, of Rush University Medical Center.
Chronic Inflammation, Dyslipidemia Puts Children, Teens With HIV at Higher CV Risk, Study Finds
January 12th 2018

Chronic Inflammation, Dyslipidemia Puts Children, Teens With HIV at Higher CV Risk, Study Finds

Mary Caffrey
The same mechanisms that cause those with long-term HIV infection to suffer higher rates of heart attacks or strokes put children born with disease at early risk of cardiovascular disease, according to a new study.
CMS Unveils New Voluntary Bundled Payment Model
January 10th 2018

CMS Unveils New Voluntary Bundled Payment Model

Mary Caffrey
The announcement comes after CMS canceled an Obama-era proposal for mandatory bundled payments in cardiac care, as well as a mandatory expansion of a program in joint replacements.
CMS Unveils New Voluntary Bundled Payment Model
January 10th 2018

CMS Unveils New Voluntary Bundled Payment Model

Mary Caffrey
The announcement comes after CMS canceled an Obama-era proposal for mandatory bundled payments in cardiac care, as well as a mandatory expansion of a program in joint replacements.
New Cholesterol Test More Accurate Than Old Test That Requires Fasting
January 3rd 2018

New Cholesterol Test More Accurate Than Old Test That Requires Fasting

Laura Joszt, MA
A newer method for calculating low-density lipoprotein (LDL) cholesterol is more accurate than the older method that required people fast before blood was drawn.
Site Logo
December 26th 2017

Perspectives of a Lipidologist: LDL Cholesterol Testing, PCSK9 Inhibitors

Mary Caffrey
Dr Todd Hobbs Discusses Identifying and Removing Barriers to Care for Obesity
December 21st 2017

Dr Todd Hobbs Discusses Identifying and Removing Barriers to Care for Obesity

Although patients and physicians both recognize the need to discuss obesity, the lack of resources, time, and expertise often prevents physicians for offering care and patients from asking for it, explained Todd Hobbs, MD, Novo Nordisk’s vice president and chief medical officer.
Conference Stories That Captivated AJMC® Readers in 2017
December 21st 2017

Conference Stories That Captivated AJMC® Readers in 2017

Samantha DiGrande
In 2017, The American Journal of Managed Care® (AJMC®) covered conferences on a range of topics: oncology, diabetes, managed care, and much more. however, the most-read coverage from conferences that AJMC® attended mostly focused on cardiology trial results, particularly the cardiovascular results of diabetes medications.
Dr Jay Edelberg Discusses Results of Alirocumab by Race and Ethnicity
December 21st 2017

Dr Jay Edelberg Discusses Results of Alirocumab by Race and Ethnicity

Trial results have shown that alirocumab (Praluent) is safe and effective across patient populations, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.
Site Logo
December 19th 2017

The CVD-Real Trial: What Can Real-World Evidence Tell Us About Primary Prevention?

Mary Caffrey
An interview with one of the authors of a large observational study that has seen findings consistent with recent cardiovascular outcomes trials in SGLT2 inhibitors.
Improved Recommendations of Deintensification in Clinical Guidelines Is Needed
December 19th 2017

Improved Recommendations of Deintensification in Clinical Guidelines Is Needed

Laura Joszt, MA
Currently, clinical guidelines offer little guidance on deintensifying care, which is critical for balancing overuse and underuse of services.
Site Logo
December 18th 2017

As Trials Report Cardiovascular Outcomes Data, What About Microvascular Results?

Andrew Smith
Evidence is more robust on kidney function but not sufficient to make drug decisions, one expert said. A whole separate trial, called CREDENCE, is examining renal function in patients taking canagliflozin.
Dr Amar Bhakta Explains a New Pathway to Prevent Heart Failure Readmissions
December 17th 2017

Dr Amar Bhakta Explains a New Pathway to Prevent Heart Failure Readmissions

A new pathway uses a multidisciplinary team to help reduce 30-day heart failure readmissions, explained Amar Bhakta, MD, of Rush University Medical Center.
Site Logo
December 14th 2017

For Those With Diabetes and CV Risk, Personalized Care Matters

Robert A. Gabbay, MD, PhD, FACP
From the Editor in Chief
Site Logo
December 13th 2017

MGH: Centralized population health coordinators help improve care for patients with chronic disease

AJMC® in the Press, December 8, 2017
December 8th 2017

AJMC® in the Press, December 8, 2017

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Dr Todd Hobbs Discusses the Advantages of Semaglutide in Type 2 Diabetes
December 5th 2017

Dr Todd Hobbs Discusses the Advantages of Semaglutide in Type 2 Diabetes

On December 5, 2017, FDA approved Novo Nordisk’s semaglutide, a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes. Todd Hobbs, MD, Novo Nordisk’s vice president and chief medical officer, spoke with The American Journal of Managed Care® just ahead of FDA’s action.
Targeting Lipids May Improve Outcomes of Abdominal Aortic Aneurysm
December 5th 2017

Targeting Lipids May Improve Outcomes of Abdominal Aortic Aneurysm

Laura Joszt, MA
Abdominal aortic aneurysm is a cardiovascular disease for which 45,000 operations are performed yearly in the United States, but a new study found that targeting lipids may improve long-term outcomes.
AJMC® in the Press, December 1, 2017
December 1st 2017

AJMC® in the Press, December 1, 2017

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Dr Eliot A. Brinton: Perspectives on PCSK9 Inhibitors
December 1st 2017

Dr Eliot A. Brinton: Perspectives on PCSK9 Inhibitors

Results from the FOURIER trial have provided convincing data that there is no downside to aggressively lowering cholesterol with PCSK9 inhibitors, and studies have shown there are cardiovascular benefits associated with Repatha, but reimbursement remains challenging, said Eliot A. Brinton, MD, FAHA, FNLA, president of the Utah Lipid Center.
<1
...
67891011121314
...
21>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo